ClinicalTrials.gg
RecruitingNCT06082102Updated Sep 15, 2025

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

A Phase 3 interventional study of Orelabrutinib and Rituximab in Relapsed/Refractory Marginal Zone Lymphoma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone — 16 open to participants now, 20 under way, 1 of them phase 3. orelabrutinib · Lymphoma, B-Cell, Marginal Zone.

Planned enrollment
Largest of 20
324 · median 51
Started
2023
with 2 others
Phase 3
Only one
of the 20
Primary completion
2028-08
later than 16 of 19 live
Registered
1st of 20
by date
Lead sponsor
1 of 20
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 20 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, this one has the largest planned enrollment, is one of 3 that started in 2023, is the only one in phase 3, reaches primary completion later than 16 of the 19 other live ones, and was the 1st registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

16 of the 20 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, or all of them as a file.
02

Study summary

Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma

03

Conditions studied

  • Relapsed/Refractory Marginal Zone Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years , either sex.
  2. Histopathologically confirmed B-cell non-Hodgkin lymphoma MZL (splenic, nodal, or extra-nodal).
  3. Prior systemic therapy including at least one anti-CD20 monoclonal antibody-containing regimen is required, with the following specifications:

    For combination therapies: Minimum of 2 completed treatment cycles For anti-CD20 monotherapy: Minimum of 4 administered doses Progression during treatment waives cycle/dose requirements

  4. disease.
  5. At least 1 confirmed through enhanced computed tomography (CT) or enhanced magnetic resonance imaging (MRI).
  6. performance status (PS) score of 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Administration of the specified anti-tumor therapies within 2 weeks prior to the first dose of the study treatment.
  2. Administration of any other product within 4 weeks prior to the first dose of the study treatment, or concurrent participation in another clinical trial.(Excluding patients who have discontinued treatment and are in long-term follow-up).
  3. Prior treatment with any types of BTK inhibitor.
  4. Patients to lenalidomide plus rituximab (R2 regimen). Refractoriness is defined as either: Failure to achieve at least partial response (PR) after completing an adequate R2 treatment course (≥2 cycles at standard doses), OR Disease progression during R2 therapy or within 6 months after the last dose.
  5. Central nervous system (CNS) lymphoma, and lymphoma with CNS or meningeal involvements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib

    Drug: Orelabrutinib · Drug: Rituximab

  • Active comparator
    Comparator

    Drug: Lenalidomide · Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. IRC-assessed PFS

    Time frame: Through study completion, an average of 5 year.

07

Study locations

16 of 19 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Aug 2028, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2023
First posted
Oct 13, 2023
StartActual
Dec 19, 2023
Primary completionEst.
Aug 31, 2028
CompletionEst.
Feb 25, 2030
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06082102
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Dec 19, 2023
Primary completion
Aug 31, 2028 (estimated)
Completion
Feb 25, 2030 (estimated)
Last update
Sep 15, 2025

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion